Home Biosimilar Antibodies Others Others Eculizumab (Anti-Complement C5)
For research use only. Not for use in humans.

Eculizumab (Anti-Complement C5)

Synonyms: Complement component C5， C5

Eculizumab (Anti-Complement C5) is a long-acting humanized monoclonal antibody targeting against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and hence inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab has the potential for haemolysis research. MW: 145.5 KD.

Eculizumab (Anti-Complement C5)

Quality Control

  • Cited in Nature Medicine for its top-tier quality
  • SDS
  • Datasheet
99

Mechanism of Action

Description
Eculizumab (Anti-Complement C5) is a long-acting humanized monoclonal antibody targeting against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and hence inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab has the potential for haemolysis research. MW: 145.5 KD.

Product Details

CAS No. 219685-50-4
Molecular Weight 145.5 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07010302 NOT_YET_RECRUITING Drug: Rituximab (R)|Drug: Eculizumab (Soliris®)|Drug: Ravuli NMOSD Massachusetts General Hospital 2026-08-01 PHASE4
NCT07520318 NOT_YET_RECRUITING Drug: bispecific anti-VEGF and anti-complement Adults With Neovascular Age-related Macular Degeneration Shenzhen Oculgen Biomedical Technology Co., Ltd. 2026-04-17 PHASE2; PHASE3
NCT07707687 RECRUITING Drug: Eculizumab Transplant-Associated Thrombotic Microangiopathy (TA-TMA) First Affiliated Hospital of Zhejiang University 2026-07-10 PHASE2
NCT07747090 NOT_YET_RECRUITING Drug: FXS6837 Capsule Paroxysmal Nocturnal Hemoglobinuria Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. 2026-12-10 PHASE3
NCT07410039 RECRUITING Drug: Eculizumab+IVMP|Drug: IVIG+IVMP|Drug: IVMP Neuromyelitis Optica Spectrum Disorder Attack Chinese PLA General Hospital 2026-02-01 PHASE4
NCT06449001 RECRUITING Drug: Danicopan Paroxysmal Nocturnal Hemoglobinuria; PNH; Extravascular Hemolysis Alexion Pharmaceuticals, Inc. 2025-08-11 PHASE3

(data from https://clinicaltrials.gov, updated on 2026-08-31)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.